Publication at Third Faculty of Medicine |
2021
Abstract
Lung cancer is among the most common malignancies with high mortality rates. Lung cancer screening showed specific mortality reduction in clinical trials due to identification of early stages, which can be treated radically.1 The clinical and pathological tumour heterogeneity makes the diagnostic and therapeutic process very complex which comes with a need of multidisciplinary team in the lung cancer management.
Actual advanced lung cancer therapy standard is based on combined treatment with immunotherapy and with targeted therapy in selected patients.